14只医药股应收账款超百亿元,血液制品企业普遍大增

北京商报
Nov 03

除了百济神州等3股预约于11月中旬披露三季报外,A股药企三季报已出齐。北京商报记者统计发现,多家药企存在应收账款高企的情况。东方财富Choice数据显示,截至三季度末,A股上市药企中,有14股应收账款超过百亿元,其中上海医药、九州通、重药控股应收账款排在前列。从应收账款同比增长率来看,今年前三季度,血液制品行业应收账款普遍大幅增加。此外,灵康药业(维权)、心脉医疗等应收账款增幅超过100%。从应收...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10